Pharmacokinetics and system linearity of tea catechins in rat
- PMID: 11334265
- DOI: 10.1080/00498250010024988
Pharmacokinetics and system linearity of tea catechins in rat
Abstract
1. The pharmacokinetics and dose proportionality of three tea catechins were assessed. 2. Male Sprague-Dawley rats (210-230 g) received intravenous (i.v.) doses (50, 100, 200 and 300 mg kg(-1)) of a decaffeinated tea fraction containing (-)-epicatechin (EC: 5%), (-)-epigallocatechin gallate (EGCG: 50%) and (-)-epicatechin gallate (ECG: 13%). 3. Catechins in plasma, urine and faeces were quantitated by HPLC. 4. A two-compartment model was utilized to describe the bi-exponential disposition exhibited by the three catechins. 5. Over this dose range, the central distribution volume (Vc) for these catechins increased significantly (p < 0.05) from 0.17-0.34 to 0.42-0.66 l kg(-1). 6. A concentration-dependent increase in the plasma free fraction of catechins that mirrored the increases in Vc was observed. 7. The estimates of steady-state volume of distribution (Vss) were between 0.68 and 2.08 l kg(-1) at the lowest dose, and tended to increase with dose. 8. Appreciable amount of catechins partitioned into red blood cells (range 9-43%) and was apparently independent of concentration. 9. The mean elimination half-life (t(1/2,beta)) for EC, EGCG and ECG across doses were 43, 124, and 222 min respectively, and were invariant with dose. 10. Parallel to Vc, a 2-3-fold dose-dependent increase (p < 0.05) in systemic clearance (CL) was observed for the three catechins. 11. Urinary recovery was highest (21-31%) for EC, while those for EGCG and ECG was only approximately 3-5%. 12. Faecal recoveries of the catechins were between 0.5 and 5%. 13. In conclusion, the pharmacokinetics of the catechins appeared to be non-linear; dose-dependent changes in xenobiotic distribution might contribute to this observation.
Similar articles
-
Mechanism of Creaming Down Based on Chemical Characterization of a Complex of Caffeine and Tea Catechins.Chem Pharm Bull (Tokyo). 2016;64(7):676-86. doi: 10.1248/cpb.c16-00131. Chem Pharm Bull (Tokyo). 2016. PMID: 27373623 Review.
-
Metabolism of green tea catechins: an overview.Curr Drug Metab. 2006 Oct;7(7):755-809. doi: 10.2174/138920006778520552. Curr Drug Metab. 2006. PMID: 17073579 Review.
-
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.Clin Cancer Res. 2005 Jun 15;11(12):4627-33. doi: 10.1158/1078-0432.CCR-04-2549. Clin Cancer Res. 2005. PMID: 15958649 Clinical Trial.
-
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability.Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1025-32. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12376503
-
Oral absorption and bioavailability of tea catechins.Planta Med. 2000 Jun;66(5):444-7. doi: 10.1055/s-2000-8599. Planta Med. 2000. PMID: 10909265
Cited by
-
Entry-inhibitory role of catechins against SARS-CoV-2 and its UK variant.Comput Biol Med. 2021 Aug;135:104560. doi: 10.1016/j.compbiomed.2021.104560. Epub 2021 Jun 10. Comput Biol Med. 2021. PMID: 34147855 Free PMC article.
-
Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.Biomolecules. 2019 Sep 16;9(9):493. doi: 10.3390/biom9090493. Biomolecules. 2019. PMID: 31527517 Free PMC article.
-
Increased BBB permeability contributes to EGCG-caused cognitive function improvement in natural aging rats: pharmacokinetic and distribution analyses.Acta Pharmacol Sin. 2019 Nov;40(11):1490-1500. doi: 10.1038/s41401-019-0243-7. Epub 2019 May 15. Acta Pharmacol Sin. 2019. PMID: 31092885 Free PMC article.
-
Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.Eur J Clin Pharmacol. 2018 Jun;74(6):775-783. doi: 10.1007/s00228-018-2436-2. Epub 2018 Feb 26. Eur J Clin Pharmacol. 2018. PMID: 29480324 Clinical Trial.
-
Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans.Pharmacol Res Perspect. 2017 Apr 17;5(3):e00305. doi: 10.1002/prp2.305. eCollection 2017 Jun. Pharmacol Res Perspect. 2017. PMID: 28603626 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources